172. Hypophosphatasia Clinical trials / Disease details
Clinical trials : 34 / Drugs : 17 - (DrugBank : 4) / Drug target genes : 3 - Drug target pathways : 6
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04980248 (ClinicalTrials.gov) | August 16, 2021 | 23/7/2021 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia | Hypophosphatasia | Biological: ALXN1850 | Alexion Pharmaceuticals | NULL | Completed | 18 Years | N/A | All | 15 | Phase 1 | United States |